Skip Navigation

JNCI Journal of the National Cancer Institute 1993 85(18):1475-1482; doi:10.1093/jnci/85.18.1475
© 1993 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Murphy, W. J.
Right arrow Articles by Longo, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, W. J.
Right arrow Articles by Longo, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 85, No. 18, 1475-1482, September 15, 1993
© 1993 Oxford University Press

Natural Killer Cells and Bone Marrow Transplantation

William J. Murphy, Craig W. Reynolds, Pierre Tiberghien, Dan L. Longo*,

Biological Response Modifiers Program Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center Frederick, Md.
Biological Carcinogenesis and Development Program, Program Resources, Inc./DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center Frederick, Md.

Correspondence to: William J. Murphy, Ph.D., Bldg. 567, Rm. 141, Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702-1201

Bone marrow transplantation is currently used in the treatment of a variety of neoplastic and nonneoplastic diseases. However, significant obstacles still limit the efficacy of this procedure. These include the occurrence of graft-versus-host disease, the failure of the marrow to engraft, the susceptibility of patients to opportunistic infections during the period of immunodeficiency after transplantation before full recovery of immune function, and finally, the recurrence of the cancer. Natural killer (NK) cells are lymphoid cells responsible for mediating a variety of immunologic and homeostatic functions. Initially described almost 20 years ago, the full range of functions carried out by these enigmatic cells continues to unfold. NK cells may be both beneficial and deleterious in bone marrow transplantation, depending on their genotype and activation status. Resting host-derived NK cells appear capable of mediating resistance to both autologous and allogeneic bone marrow cell grafts. At the other end of the spectrum, the transfer of activated NK cells of donor type appears to produce multiple beneficial effects during both syngeneic and allogeneic bone marrow transplantation. Here, we review and attempt to reconcile the literature concerning the basic biology of NK cells and their effects on hematopoiesis, both in vitro and in vivo. We also discuss the current issues in bone marrow transplantation and the potential role NK cells may play in determining the outcome of the marrow graft, the occurrence of graft-versus-host disease, and the generation of a graft-versus-tumor response when bone marrow transplantation is used for the treatment of cancer. [J Natl Cancer Inst 85:1475–1482, 1993]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. Raziuddin, D. L. Longo, M. Bennett, R. Winkler-Pickett, J. R. Ortaldo, and W. J. Murphy
Increased bone marrow allograft rejection by depletion of NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens
Blood, September 26, 2002; 100(8): 3026 - 3033.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Raziuddin, M. Bennett, R. Winkler-Pickett, J. R. Ortaldo, D. L. Longo, and W. J. Murphy
Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2b bone marrow cell allografts
Blood, June 15, 2000; 95(12): 3840 - 3844.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
Q. H. Nguyen, R. L. Roberts, B. J. Ank, S.-J. Lin, C. K. Lau, and E. R. Stiehm
Enhancement of Antibody-Dependent Cellular Cytotoxicity of Neonatal Cells by Interleukin-2 (IL-2) and IL-12
Clin. Vaccine Immunol., January 1, 1998; 5(1): 98 - 104.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
A. Raziuddin, D. L. Longo, L. Mason, J. R. Ortaldo, M. Bennett, and W. J. Murphy
Differential Effects of the Rejection of Bone Marrow Allografts by the Depletion of Activating Versus Inhibiting Ly-49 Natural Killer Cell Subsets
J. Immunol., January 1, 1998; 160(1): 87 - 94.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Gardiner, A. O' Meara, and D. J. Reen
Differential Cytotoxicity of Cord Blood and Bone Marrow-Derived Natural Killer Cells
Blood, January 1, 1998; 91(1): 207 - 213.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.